Hyperthyroidism management during pregnancy and lactation (Review)

xlomafota13 shared this article with you from Inoreader Hyperthyroidism management during pregnancy and lactation (Review) Via Experimental and therapeutic medicine Exp Ther Med. 2021 Sep;22(3):960. doi: 10.3892/etm.2021.10392. Epub 2021 Jul 7. ABSTRACT Thyroid dysfunction is a significant public health issue, affecting 5-10 more women compared to men. The estimated incidence is up to 12% and only for women the treatment rises up to 4.3 billion dollars annually. Thyroid pathology can have a major impact on female fertility and it can only be detected when preconception tests are performed. Untreated or poorly treated hyperthyroidism in a mother can affect the fetal development and pregnancy outcome. Between 0.1 and 0.4% of the pregnancies are affected by clinical hyperthyroidism. Thyroid dysfunction is associated with higher rates of pregnancy loss. Hyperthyroidism can complicate fetal health problems intrauterinely and in the neonatal period. The TSH receptor is stimulated by TSH and HCG which has a similar structure. This can lead to gestational thyrotoxicosis. Hyperthyroidism can be treated wit h propylthiouracil or methimazole and in selected cases, surgical treatment or radioactive iodine can be chosen. In pregnancy, the most used treatment is represented by propylthiouracil which can be used from the first trimester. The aim of this review is to assess the current data regarding the impact of thyroid dysfunction on pregnancy and to synthesize the treatment options during pregnancy and lactation. PMID:34335902 | PMC:PMC8290437 | DOI:10.3892/etm.2021.10392 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.